Literature DB >> 24177046

Down-regulation of Nogo-A by collagen scaffolds impregnated with bone marrow stromal cell treatment after traumatic brain injury promotes axonal regeneration in rats.

Asim Mahmood1, Hongtao Wu2, Changsheng Qu3, Selina Mahmood4, Ye Xiong5, David Kaplan6, Michael Chopp7.   

Abstract

Nogo-A is a major form of growth inhibitory molecule (growth-IM) which inhibits axonal regeneration and neurite regrowth after neural injury. Bone marrow stromal cells (MSCs) have been shown to inhibit Nogo-A expression in vitro and in cerebral ischemic animal models. The present study was designed to investigate the effects of treatment with human MSCs (hMSCs) impregnated into collagen scaffolds on the expression of Nogo-A and axonal plasticity after traumatic brain injury (TBI). Adult male Wistar rats were injured with controlled cortical impact and treated either with saline, hMSCs-alone or hMSCs impregnated into collagen scaffolds (scaffold+hMSC) transplanted into the lesion cavity 7 days after TBI. Rats were sacrificed 14 days after TBI and brain tissues were harvested for immunohistochemical studies, Western blot analysis, laser capture microdissections and qRT-PCR to evaluate axonal density and Nogo-A protein and gene expressions. Our data showed that treatment of TBI with scaffold+hMSC significantly decreased TBI-induced Nogo-A protein expression and increased axonal density compared to saline and hMSC-alone treatments. In addition, scaffold+hMSC transplantation decreased Nogo-A transcription in oligodendrocytes after TBI. Scaffold+hMSC treatment was superior to hMSC-alone treatment in suppressing Nogo-A expression and enhancing axonal regeneration after TBI. Our data suggest that transplanting hMSCs with scaffolds down-regulates Nogo-A transcription and protein expression which may partially contribute to the enhanced axonal regeneration after TBI.
© 2013 Published by Elsevier B.V.

Entities:  

Keywords:  Axonal regeneration; Bone marrow stromal cells; CNS; ECM; Growth-IMs; LCM; MAG; MSCs; Nogo-A; OMgp; PNS; Traumatic brain injury; central nervous system; extracellular matrix; growth inhibitory molecules; laser capture microdissection; marrow stromal cells; myelin associated glycoproteins; oligodendrocytic myelin glycoprotein; peripheral nervous system

Mesh:

Substances:

Year:  2013        PMID: 24177046     DOI: 10.1016/j.brainres.2013.10.045

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  5 in total

Review 1.  Investigational agents for treatment of traumatic brain injury.

Authors:  Ye Xiong; Yanlu Zhang; Asim Mahmood; Michael Chopp
Journal:  Expert Opin Investig Drugs       Date:  2015-03-01       Impact factor: 6.206

Review 2.  In vitro augmentation of mesenchymal stem cells viability in stressful microenvironments : In vitro augmentation of mesenchymal stem cells viability.

Authors:  Fatemeh Amiri; Ali Jahanian-Najafabadi; Mehryar Habibi Roudkenar
Journal:  Cell Stress Chaperones       Date:  2014-12-20       Impact factor: 3.667

3.  Systemic administration of cell-free exosomes generated by human bone marrow derived mesenchymal stem cells cultured under 2D and 3D conditions improves functional recovery in rats after traumatic brain injury.

Authors:  Yanlu Zhang; Michael Chopp; Zheng Gang Zhang; Mark Katakowski; Hongqi Xin; Changsheng Qu; Meser Ali; Asim Mahmood; Ye Xiong
Journal:  Neurochem Int       Date:  2016-08-15       Impact factor: 3.921

4.  Diffusion-Derived Magnetic Resonance Imaging Measures of Longitudinal Microstructural Remodeling Induced by Marrow Stromal Cell Therapy after Traumatic Brain Injury.

Authors:  Lian Li; Michael Chopp; Guangliang Ding; Changsheng Qu; Siamak P Nejad-Davarani; Esmaeil Davoodi-Bojd; Qingjiang Li; Asim Mahmood; Quan Jiang
Journal:  J Neurotrauma       Date:  2016-05-13       Impact factor: 5.269

Review 5.  Cell-based and pharmacological neurorestorative therapies for ischemic stroke.

Authors:  Poornima Venkat; Yi Shen; Michael Chopp; Jieli Chen
Journal:  Neuropharmacology       Date:  2017-09-01       Impact factor: 5.250

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.